Clinical Trial Update: Drug Use Investigation for FLOLAN (Epoprostenol) Injection 0.5mg・1.5mg

View source ↗

Summary

Completed clinical trial update on the use of FLOLAN (epoprostenol) Injection at 0.5 mg and 1.5 mg for cardiovascular disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease

Drugs mentioned

• FLOLAN (EPOPROSTENOL SODIUM)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cardiovascular Disease | Status: COMPLETED